73 results
Keyword Cetirizine Remove keyword
-
List item
Referral: Zyrtec
cetirizine, Article 30 referrals
Status: European Commission final decision, opinion/position date: 30/05/2008, EC decision date: 06/10/2008, Last updated: 16/10/2008Non-Proprietary Name (INN): cetirizine: Background information PDF … About this medicineZyrtec cetirizineAbout this procedureCHMP/296484/08 … Non-Proprietary Name (INN): cetirizine BACKGROUND INFORMATION … -
List item
National expert: Karl-Friedrich Lukat, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 79.82 KB | PDF
- Curriculum Vitae - 20.88 KB | PDF
KF, Bachert C: Wirkung von Cetirizin und Fluticasonpropionat-Nasenspray … saisonalen allergischen Rhinitis. [Effect of cetirizine and fluticasone propionate … once daily bilastine with cetirizine and placebo for the treatment … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,27-30 May 2008
CHMP, Last updated: 02/06/2008cetirizine), from UCB, used as antiallergic … Zyrtec/Reactine and associated names (cetirizine), from UCB, used as antiallergic … -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 24-27 May 2006
CHMP, Last updated: 02/06/2006cetirizine dihydrochloride 10 mg … generic medicines containing cetirizine dihydrochloride 10 mg (film … -
List item
Human medicine European public assessment report (EPAR): Stocrin
efavirenz, HIV Infections
Date of authorisation: 28/05/1999, Revision: 47, Authorised, Last updated: 05/10/2022 -
List item
Human medicine European public assessment report (EPAR): Sustiva
efavirenz, HIV Infections
Date of authorisation: 28/05/1999, Revision: 46, Authorised, Last updated: 17/10/2022 -
List item
Human medicine European public assessment report (EPAR): Neoclarityn
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 15/01/2001, Revision: 45, Authorised, Last updated: 15/12/2022 -
List item
Human medicine European public assessment report (EPAR): Azomyr
desloratadine, Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
Date of authorisation: 15/01/2001, Revision: 51, Authorised, Last updated: 15/12/2022 -
List item
Human medicine European public assessment report (EPAR): Aerinaze
desloratadine, pseudophedrine sulfate, Rhinitis, Allergic, Seasonal
Date of authorisation: 30/07/2007, Revision: 22, Authorised, Last updated: 07/12/2022 -
List item
Human medicine European public assessment report (EPAR): Xolair (updated)
omalizumab, Asthma; Urticaria
Date of authorisation: 25/10/2005, Revision: 44, Authorised, Last updated: 01/02/2023 -
List item
Human medicine European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
efavirenz, emtricitabine, tenofovir disoproxil succinate, HIV Infections
Date of authorisation: 08/02/2018,
, Revision: 9, Authorised, Last updated: 05/12/2022
-
List item
Human medicine European public assessment report (EPAR): Aripiprazole Sandoz
aripiprazole, Schizophrenia; Bipolar Disorder
Date of authorisation: 20/08/2015,, Revision: 9, Authorised, Last updated: 01/09/2022
-
List item
Human medicine European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna)
CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2), COVID-19 virus infection
Date of authorisation: 06/01/2021,
, 
, Revision: 35, Authorised, Last updated: 22/12/2022
-
List item
Human medicine European public assessment report (EPAR): Sarclisa (updated)
Isatuximab, Multiple Myeloma
Date of authorisation: 30/05/2020,, Revision: 6, Authorised, Last updated: 18/01/2023
oral (or equivalent [e.g., cetirizine, promethazine, dexchlorpheniramine … -
List item
Human medicine European public assessment report (EPAR): Efavirenz Teva
efavirenz, HIV Infections
Date of authorisation: 09/01/2012,, Revision: 11, Authorised, Last updated: 10/02/2022
-
List item
Human medicine European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan
efavirenz, emtricitabine, tenofovir disoproxil maleate, HIV Infections
Date of authorisation: 05/09/2017,, Revision: 13, Authorised, Last updated: 14/09/2022
-
List item
Human medicine European public assessment report (EPAR): Maviret
glecaprevir, pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017,
, Revision: 17, Authorised, Last updated: 23/08/2022
-
List item
Human medicine European public assessment report (EPAR): Capecitabine Medac
capecitabine, Colorectal Neoplasms
Date of authorisation: 19/11/2012,, Revision: 12, Authorised, Last updated: 25/04/2022
-
List item
Human medicine European public assessment report (EPAR): Elzonris
tagraxofusp, Lymphoma
Date of authorisation: 07/01/2021,, 
, 
, Revision: 5, Authorised, Last updated: 23/09/2022
-
List item
Human medicine European public assessment report (EPAR): Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva
efavirenz, emtricitabine, tenofovir disoproxil phosphate, HIV Infections
Date of authorisation: 17/07/2017,, Revision: 8, Authorised, Last updated: 18/05/2022
-
List item
Human medicine European public assessment report (EPAR): Telzir
fosamprenavir calcium, HIV Infections
Date of authorisation: 12/07/2004, Revision: 48, Authorised, Last updated: 23/08/2022 -
List item
Human medicine European public assessment report (EPAR): Kaftrio (updated)
ivacaftor, tezacaftor, elexacaftor, Cystic Fibrosis
Date of authorisation: 21/08/2020,, , Revision: 11, Authorised, Last updated: 16/01/2023
-
List item
Human medicine European public assessment report (EPAR): Granpidam
sildenafil citrate, Hypertension, Pulmonary
Date of authorisation: 14/11/2016,, Revision: 7, Authorised, Last updated: 26/07/2022
-
List item
Human medicine European public assessment report (EPAR): Livmarli
Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022,, , , Authorised, Last updated: 14/12/2022
-
List item
Human medicine European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
dinutuximab beta, Neuroblastoma
Date of authorisation: 08/05/2017,, , , Revision: 12, Authorised, Last updated: 14/12/2022